Figure 2. Tumor Response.

A, Waterfall plot depicting Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 response to capecitabine, oxaliplatin, and pembrolizumab (COP) therapy before resection (n = 16). Corresponding pathologic response by College of American Pathologists (CAP) criteria, pathologic differentiation, and baseline programmed cell death ligand 1 combined positive scoring (PD-L1 CPS) score are shown. B, Comparison of baseline endoscopic ultrasonography (EUS) with pathologic staging by TNM criteria (T stage, left; N stage, right). C, Correlation of baseline EUS staging with pathologic response after COP therapy by CAP criteria.